Search results

Page 1 of 4

Your search for atherosclerosis returned 33 results

Order results by:

Target: GPR132 (Class A Orphans)
Consequences of altering gene expression: deficiency affects atherosclerosis in a tissue-specific manner. ApoE dependent pro-atherogenic phenotype is observed
Consequences of altering gene expression: atherosclerosis in low-density lipoprotein receptor knockout mice. Reduction in aortic lesion coverage, macrophage accumulation
Consequences of altering gene expression: ability to engulf apoptotic cells in vitro, and promotes macrophage activation and atherosclerosis in vivo
Consequences of altering gene expression - comment: atherosclerosis. One study investigating GPR132 knockout in LDLR-/- and ApoE-/- mice, suggested an ApoE-dependent
Ligand: darapladib
Comments: clinical drug candidates with potential to reduce the risk of atherosclerosis and associated clinical sequelae .
Clinical use: Phase 3 clinical trial (NCT01067339) as a treatment for atherosclerosis, but GSK has discontinued further development.
Target: regulator of G-protein signaling 1 (R4 family)
Mutations/pathophysiology - disease: Atherosclerosis susceptibility
Mutations/pathophysiology - comment: Vascular diseases: Atherosclerosis AND aortic aneurysms
Target: P2Y1 receptor (P2Y receptors)
Consequences of altering gene expression: P2Y1 receptor deficiency resulted in a reduction of atherosclerosis in ApoE knockout mice.
Physiological function - description: Atherosclerosis enhancement
Ligand: GSK1016790A
Bioactivity comments: indicative of a potential for TRPV4 activation to be used as a therapeutic approach to treat atherosclerosis .
Ligand: alirocumab
Mechanism of action: available for removal of LDL-cholesterol from the blood and this reduces the risk of atherosclerosis.
Ligand: sarpogrelate
Clinical use: atherosclerosis. There is no information regarding approval for clinical use of this drug on the US FDA or European
Ligand: BMS-582949
Clinical use: atherosclerosis (NCT00570752) and rheumatoid arthritis (NCT00605735). There are no currently active trials for this compound
Ligand: rilapladib
Comments: development to determine their effects on reducing the risk of atherosclerosis and associated clinical sequelae .
Target: ADGRE2 (Adhesion Class GPCRs)
Tissue distribution - tissues: rheumatoid arthritis, in liver and lung abscesses, in severe acute suppurative appendicitis and in atherosclerosis

1 2 3 4

Target search page
Ligand search page